UNCOVERING THE 95% DARK MATTER
▸ We believe that the cure to immunologic disorders is hidden amongst a vast network of gut microbial DNA.
▸ We built the largest gut-DNA atlas to access novel therapeutic chemical space.
Our Process
Multi-omic Data
Generating patient-derived clinical metadata and biospecimen samples
AI
Predicting viable biomarkers and therapeutic candidates
Synthetic Biology
Production of small molecules via cell-free expression
Screening Assays
Functional assays for high throughput phenotypic screening
We are using proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and novel therapeutics for the most challenging immunologic disorders.
Open Positions
Founders Associate / Chief of Staff (South San Francisco)
Senior Bioinformatics Scientist: Metagenomics and Metabolomics (South San Francisco)
Research Assistant in Cell Free Protein Synthesis (South San Francisco)
Team
Ayin Vala, MS
Co-founder, Chief AI Officer
Claire Toney, BS
Research Assistant
Dora Yu, PhD
Scientist
Hanane Arib, MS
Head of Clinical
Operations
Kareem Barghouti, MBA
Co-founder, CEO
Lanying Ma, PhD
Senior Bioinformatics Scientist
Mark Ashwell, PhD
Head of Chemistry
Peter McCaffrey, MD
Co-founder, CTO
Riccardo Guidi, PhD
Associate Director, Immunology Research
Subramanya Rao, PhD
Scientist
Alex Cogdill, PhD
Cancer Immunology
Jonathan Kotula, PhD
Synthetic Biology
Matt Durrant, PhD
Computational Biology
Stephen Nayfach, PhD
Bioinformatics
Tomer Altman, PhD
Bioinformatics
Advisors
Elaine Stracker, JD, PhD
Former EVP & General Counsel at Pharmacyclics
Ken Blount, PhD
CSO Biochemistry Rebiotix
Kovi Bessoff, MD, PhD
Co-founder, CSO
Milad Alucozai, MS, MPH
Serial Entrepreneur, Advisor to AstraZeneca
Mohan Iyer, MBA
Former COO at Pendulum,
CBO at Second Genome
Nadim Ajami, PhD
Executive Director of Microbiome at MD Anderson
Phil Jones, PhD
VP of Therapeutic Discovery at MD Anderson
Wasim Malik, PhD
Managing Partner at Iaso, Former CDO at Roivant
Supported By
Partners
Highlighted Press Release
Jan 2022 | VastBiome Announces PARADIGM, a Large Exploratory Prospective Data Collection
Nov 2021 | Bristol Myers Squibb awards “Golden Ticket” to VastBiome
Dec 2020 | VastBiome Raises $4.5 Million in Seed Funding
Oct 2020 | Startus Insights selects VastBiome as Top 5 BioTech Startups in microbiome analysis to watch out for
Sep 2020 | Stanford’s StartX accepts VastBiome to its cohort of MedTech companies
Sep 2020 | NYU’s Endless Frontier Labs accepts VastBiome to help grow its business
Apr 2020 | VastBiome to present at National Health Symposium
Feb 2020 | VastBiome selected to present at Microbiome Movement Drug Development in London
Oct 2019 | Medstartr publishes on VastBiome
Sep 2019 | VastBiome selected to present at Stanford Medicine’s Frontier of AI-Assisted Medicine
July 2019 | UCSF Rosenman Institute Interviews VastBiome on Cancer Immunology & the Microbiome
May 2019 | VastBiome interviewed by Antimicrobial Regeneration Consortium
Mar 2019 | VastBiome wins grant at SXSW
Mar 2019 | VastBiome’s poster accepted to NVIDIA’s GTC Conference
Oct 2018 | Illumina announces VastBiome into Illumina Accelerators Eighth Investment Cycle
Contact Us
LOCATION
280 Utah Ave. South San Francisco, CA
PHONE
(650) 479-5539
info@vastbiome.com